Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2018 07:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Provides Update on its Cannabis-based Pharmaceuticals Initiatives

TORONTO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) ("Revive" or the “Company”), a specialty cannabis company focused on the research,...
August 28, 2018 07:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Provides Corporate Update

TORONTO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research,...
August 22, 2018 07:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Applies To FDA For Orphan Drug Designation of Cannabidiol For Treatment Of Liver Transplantation

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive” or the “Company”), a specialty medical cannabis company, today announced that...
June 27, 2018 10:53 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Treatment of Autoimmune Hepatitis

TORONTO, June 27, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) ("Revive" or the "Company"), a company focused on the research, development and...
June 27, 2018 07:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Treatment of Autoimmune Hepatitis

TORONTO, June 27, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) ("Revive" or the "Company"), a company focused on the research, development and...
June 13, 2018 07:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics and WeedMD Sign Medical Cannabis R&D Supply and Collaboration Agreements

TORONTO, June 13, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX-V:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive”), a company focused on the research, development and commercialization of novel...
May 30, 2018 17:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2018

TORONTO, May 30, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization...
May 10, 2018 08:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces Acceptance of Abstract for Cannabinoid Delivery Technology at 29th International Conference on Polyphenols and the 9th Tannin Conference

TORONTO, May 10, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization...
April 30, 2018 07:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces Exclusive License Agreement with Wisconsin Alumni Research Foundation for Cannabinoid Delivery Technology

TORONTO, April 30, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization...
March 28, 2018 16:30 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Retained Mi3 Communications for Investor Relations Services

TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization...